| 16.56 -0.61 (-3.55%) | 01-08 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 21.18 | 1-year : | 22.98 |
| Resists | First : | 18.13 | Second : | 19.68 |
| Pivot price | 17 |
|||
| Supports | First : | 15.64 | Second : | 13.01 |
| MAs | MA(5) : | 16.48 |
MA(20) : | 17.39 |
| MA(100) : | 15.4  |
MA(250) : | 13.38 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 28.7 |
D(3) : | 22 |
| RSI | RSI(14): 45.7 |
|||
| 52-week | High : | 19.7 | Low : | 7.8 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BCAX ] has closed above bottom band by 33.8%. Bollinger Bands are 33.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 17.55 - 17.65 | 17.65 - 17.74 |
| Low: | 16 - 16.11 | 16.11 - 16.2 |
| Close: | 16.41 - 16.58 | 16.58 - 16.73 |
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.
Wed, 24 Dec 2025
Hyep Ivan, Bicara Therapeutics CFO, sells $168k in BCAX stock - Investing.com India
Tue, 25 Nov 2025
Bicara Therapeutics president Cohlhepp sells $225k in shares - Investing.com
Thu, 16 Oct 2025
Bicara Therapeutics president Cohlhepp sells $226942 in shares - Investing.com
Wed, 15 Oct 2025
Bicara Therapeutics CEO Mazumdar sells $466k in shares - Investing.com
Wed, 08 Oct 2025
Bicara Therapeutics CFO Hyep Ivan sells $553,198 in shares - Investing.com
Wed, 08 Oct 2025
Bicara therapeutics president Cohlhepp sells $911k in shares - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 55 (M) |
| Shares Float | 24 (M) |
| Held by Insiders | 12.1 (%) |
| Held by Institutions | 91.8 (%) |
| Shares Short | 8,020 (K) |
| Shares Short P.Month | 7,220 (K) |
| EPS | 5.38 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.38 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -18.6 % |
| Return on Equity (ttm) | -26.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.58 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -113 (M) |
| Levered Free Cash Flow | -75 (M) |
| PE Ratio | 3.07 |
| PEG Ratio | 0 |
| Price to Book value | 2.24 |
| Price to Sales | 0 |
| Price to Cash Flow | -8.03 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|